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Original Article
Efficacy and safety of quinine loading dose in patients with severe 
Falciparum malaria at a tertiary care hospital in Pakistan
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Syed Imran Ayaz,7 Mehmood Riaz,8 Mohammed Junaid Patel,9 Jaweed Akhtar,10 Mohammed Asim Beg11
Department of Medicine,1,8-10 Medical Graduates,2,3,5-7 Department of Pathology and Microbiology,4,11
Aga Khan University Hospital, Karachi, Pakistan.
Abstract
Objective: To compare the clinical outcomes of a loading dose regimen of quinine with a uniform dose regimen
in patients with severe falciparum malaria. 
Methods: A retrospective chart review of 315 patients admitted with severe falciparum malaria and treated with
quinine at a tertiary care teaching hospital of Karachi, Pakistan during 1999-2006 was conducted. Group A with
103 patients (32.7%) was given an initial loading dose of quinine while group B with 212 patients (67.3%) did not
receive the loading dose. The two groups were compared in terms of reduction of parasite load, resolution of
fever, recovery of consciousness and incidence of adverse effects. Outcome parameters were measured on the
third day of therapy. 
Results: More individuals in group A (62.1%) were afebrile as compared to group B (54.7%) at day 3 of therapy.
Patients in group B showed greater reduction in parasitaemia (47.2% at baseline to 4.7% on day 3) as compared
to group A (56.3 % at baseline to 9.7% on day 3). Following therapy, fewer patients in group B had altered
consciousness (7.1% at baseline to 4.7% on day 3) as compared to patients in group A (7.8% at baseline to 5.8%
on day 3). However, these associations were not statistically significant. The incidence of thrombocytopenia was
higher in Group A (5.8%) as compared to Group B (0.9%). 
Conclusion: Although quinine loading dose may be more effective than uniform dose in rapid fever clearance;
it also appears to be associated with higher toxicity. Uniform dose of quinine may be prescribed in severe
falciparum malaria in view of its better safety profile.
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Introduction 
Falciparum malaria is a severe and a potentially life-
threatening parasitic disease with increasing prevalence in
most endemic regions of the world. This translates into
devastating health and socio-economic consequences;
especially in areas where there is increasing drug resistance in
the causative organism or where the cases are inappropriately
managed.1,2 The disease affects more than 500 million people
and causes 2-3 million deaths each year worldwide.2-4Malaria
is also a major health problem in Pakistan, with an estimated
number of annual episodes of about 1.6 million. Of these,
about 33% are reported as falciparum malaria cases. Most of
the disease episodes have been recorded in the post-monsoon
period (August-November); the stagnant water pools
providing optimal breeding conditions for the mosquitoes.5
Falciparum malaria is associated with significant
morbidity and mortality.2,6 In particular, severe falciparum
malaria may be complicated by Acute Renal Failure (ARF),
Disseminated Intravascular Coagulation (DIC), Cerebral
Malaria, Hypoglycaemia, Metabolic Acidosis, Pneumonia,
Acute Respiratory Distress Syndrome (ARDS) and
Anaemia.4,7
Early and effective treatment of severe falciparum
malaria may shorten its duration and prevent development of
complications with a reduction in associated mortality.
However, there is little consensus with regards to the most
optimum modus operandi for the therapeutic management of
this condition. Quinine is still being used as a first-line drug
in falciparum malaria since resistance to Chloroquine has
been widely reported from many parts of the world including
Pakistan.2,4,6,8 The World Health Organization (WHO)
recommends in its handbook for management of severe
malaria, that the course of treatment with Quinine may follow
a high initial Loading Dose (qLD) regimen of 20mg/kg of
body weight followed by Maintenance Dose (qMD) of
10mg/kg repeated 8 hourly to complete a 7 day course of
treatment.4
However, according to a Cochrane Review of 2004,9
the use of an initial loading dose of quinine remains debatable.
Randomized controlled trials (RCTs) assessing this subject are
few and far between; only 4 trials (n=144) fulfilled the
inclusion criteria of this Cochrane Review. It was concluded
that while qLD was associated with fewer deaths, this
association was not statistically significant. qLD caused a
reduction in fever clearance time and parasite clearance time
but there was no statistically significant impact on the recovery
of consciousness, neurological sequelae, as convulsions. 
Thus on one hand, there are studies that have
illustrated the use of a high initial IV Quinine Loading Dose
as being beneficial;2,10-12 on the other hand, there are studies
that negate the advantages of the Loading Dose Regime over
standard treatment of maintenance dose for
severe/complicated malaria.6,13,14
Thus, it is important to collect more data on the subject
in order to delineate the direction of the therapeutic trend with
regards to use of loading dose of quinine. Current data are
insufficient to directly demonstrate the benefits or drawbacks
of this form of treatment. Therefore, the current study was
undertaken to assess the efficacy and safety of Quinine
Loading Dose in the treatment of severe falciparum malaria in
a malaria endemic geographical region of the world in order to
evaluate its effect on various parameters such as (1) reduction
of parasite load, (2) resolution of fever, (3) recovery of
consciousness and (4) adverse effects. The results of this study
may, therefore, help improve current prescribing practices in
the treatment of severe falciparum malaria. 
Methods 
This retrospective review of patient charts was
conducted in the Department of Medicine, Aga Khan
University Hospital (AKUH) Karachi, Pakistan. A
computerized data base search for anonymous patient
information was conducted under the guidelines of Ethical
Review Committee (ERC) of the Aga Khan University
Hospital. No patient was individually identified and the data
was obtained in an anonymous fashion without ever alluding
to the identity of the patient. The data of hospitalized adult
patients was extracted meeting the following inclusion
criteria: a) age 15 or above, b) admitted with the diagnosis of
'Severe Falciparum Malaria' c) admitted during an 8 year
period from January 1, 1999 to December 31, 2006 d) treated
with intravenous (IV) or oral Quinine. All hospitalized
patients were considered to have severe malaria based on the
categorization as per WHO classification for severe
falciparum malaria.4 We excluded those patients who were
negative for Malarial Parasite (MP) on admission or who
were diagnosed on the basis of Immuno-chromatographic
(ICT) test. Quantitative assessment of parasitemia through
MP test was categorized as 'heavy' when there were more
than 1000 parasites/100 high power microscopic field,
'moderate' when there were 11-1000 parasites/100 high
power microscopic fields and "scanty" when there were 1-10
parasites/100 high power microscopic fields. Two
comparison groups were made based on the administration of
quinine regime. The loading dose (qLD) regime consisted of
20mg/kg of body weight given IV followed by maintenance
dose of 10 mg/kg body weight given either IV or oral
repeated 8 hourly for 5-7 days. The "no loading" dose regime
comprised of quinine maintenance dose (qMD) only. The
primary comparison between the two groups in terms of
different parameters was done on the 3rd day after therapy
was administered. Data was entered and analyzed using
Windows Statistical Package for Social Sciences (SPSS)
version 14.15 Data were described calculating means and
standard deviations for continuous variables and frequencies
for categorical variables. Univariate analysis was conducted
defining dependent variables on the basis of first dose of
quinine therapy and it was categorized in two groups, i.e.,
quinine loading dose (qLD) group and no loading dose group
(qMD). Student's t-test was used to compare means among
qLD and qMD groups. Chi-square test or Fisher's exact test,
as appropriate, were used to compare categorical independent
variables among the two groups. A p-value of < 0.05 was
considered statistically significant; unless otherwise
specified. 
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Results
A total of 315 patients were included in this study. The
mean age was 38.5 ± 16.8 years with 239 (75.9%) males and
76 (24.1%) females. Most patients (87.9%) were admitted
through emergency room (ER) while the remaining were
admitted through consulting clinics. The majority (69.8%) of
the patients were admitted during a four month post-monsoon
period from August to November. The initial Loading dose of
quinine (qLD) was given to Group A with 103 (32.7%)
patients. Group B with 212 (67.3%) patients did not receive
qLD. All patients received maintenance dose, either IV (33%)
or oral (67%). 
Thrombocytopenia, cerebral malaria, anaemia,
pneumonia, Acute Respiratory Distress Syndrome (ARDS),
metabolic acidosis, hypoglycaemia, volume depletion and
jaundice were complications equally distributed (p>0.05) in
the two groups at the time of presentation. Acute renal failure
(p=0.008) and disseminated intravascular coagulation (DIC)
(p=0.008) were complications more common in patients in
Group A. A comparison of other clinical parameters between
Vol. 61, No. 1, January 2011 29
Table-1: Socio demographic characteristics and other baseline features by quinine group in patients
with severe falciparum malaria admitted at AKUH from 1999-2006.
Characteristic Group A Group B p-value
(n = 103) % (n = 212) %
Gender
Male 69.9 78.8 0.084
Female 30.1 21.2
Mean Age in years $ 38.2 ± 16.7 38.7 ± 17.0 0.793
Mean Duration of fever in days @ 7.3 ± 6.6 7.4 ± 6.6 0.846
Malaria complications present at baseline
Thrombocytopenia 27.2 25 0.677
Acute renal failure 17.5 7.5 0.008
Cerebral malaria 10.7 9 0.626
Anaemia 9.7 9 0.83
Disseminated intravascular coagulation 9.7 2.4 0.008 #
Pneumonia 7.8 2.8 0.076 #
Acute respiratory distress syndrome 6.8 2.4 0.064 #
Metabolic acidosis 3.9 1.9 0.446 #
Hypoglycaemia 1.9 1.9 0.999 #
Volume depletion 37.9 31.6 0.27
Jaundice 34 31.1 0.611
Presence of altered consciousness at baseline (as measured by GCS < 14) 7.8 7.1 0.825
Mean temperature documented at baseline (degree Celsius) 38 ± 1.2 37.9 ± 1.17 0.104
Malarial parasite load at baseline 
Heavy 13.6 8.5
Moderate 42.7 38.7 0.039
Scanty 43.6 52.8
$ Information missing in 3 patients; @ Information missing in 11 patients; # Fisher exact test p-value.
Table-2 Comparison of outcomes between groups based on type of quinine therapy received.
Outcome measure Group A Group B p-value
(n = 103) % (n = 212) %
Parasite load at day 3
Heavy 2.9 0
Moderate 6.8 4.7 0.08
Scanty 36.9 36.8
Negative MP 53.4 58.5
Presence of altered consciousness at day 3 (as measured by GCS ? 14) 5.8 4.7 0.674
Fever resolution at day 3 (temperature < 38 degree Celsius for last 24 hours) 62.1 54.7 0.59
Adverse effects of quinine therapy
Vomiting 5.8 3.3 0.366 #
Cinchonism / tinnitus 5.8 4.2 0.577 #
Arrhythmias 1.9 1 0.250 #
Hypoglycemia 1.9 0.5 0.999 #
Thrombocytopaenia 5.8 0.9 0.017 #
Pulmonary oedema 1 0 0.327 #
# Fisher exact test p-value.
the two groups including altered level of consciousness (GCS
14 or less), documented mean temperature and quantitative
MP on microscopy is shown in Table-1.
Table-2 shows a comparison of the outcomes between
the two groups. These were measured on the third day of the
administration of therapy. It was seen that by third day of
therapy, the difference in quantitative parasitaemia between
the two groups was insignificant (p=0.08). In terms of
recovery of consciousness at day 3, the two groups were
again comparable (p=0.674). There was no statistically
significant difference between the two groups in terms of
fever resolution at day 3 (p=0.59). However, more
individuals in Group A were afebrile as compared to Group B
(62.1 % vs. 54.7%). 
Group A and Group B were also comparable with
regards to the majority of the in-hospital quinine-specific
major side effects including cinchonism/tinnitus (headache,
dizziness, hearing loss, and ringing in the ears)
nausea/vomiting, hypoglycaemia, pulmonary oedema and
cardiac arrhythmia (prolongation of QT interval). The groups,
however, showed a statistically significant difference with
regards to the incidence of thrombocytopenia (platelet count
< 150,000 cells per microliter); more patients who had
received qLD showed this adverse effect (p=0.017). 
Discussion 
This study assessed the effectiveness and beneficial
aspects of incorporating the rationale of a high initial IV
quinine loading dose in the treatment of adult patients with
moderate to severe and/or complicated falciparum malaria.
Demographic details in this study showed that majority of
patients were males possibly as a result of more exposure to
the vectors of malaria although no evidence was found to
substantiate this internationally.
According to literature, quinine has evolved to be the
first-line drug for severe / complicated falciparum
malaria.2,4,6,9,16,17 As per standard recommendations of
WHO,4 the globally advised rationale comprises of high initial
loading dose of quinine followed by a maintenance dose. 
Our analysis showed that only one third of the patients
received qLD, which in addition to the attending physician's
choice may be attributed to either lack of ascertainment of
prior drug administration, or use of quinine and its derivatives
in past 12 hours.4,6 Results of our study show success in early
achievement of fever clearance in patients who received qLD,
but parasite clearance (negative MP) was not significant. 
Assessment of scientific literature and discussions
over the efficacy and advantages of quinine loading dose
regime revealed that qLD may contribute a beneficial effect
in terms of Fever Clearance Time (FCT) as well as Parasite
Clearance Time (PCT).2,9,10,14,18-20
Patients given qLD showed an improvement in the
level of consciousness, accounting for early recovery of
mental stability. Fargier et al19 commented on significant
reduction of coma recovery time in patients on qLD therapy.
However, the Cochrane Review9 advocates insufficient
evidence to determine association of qLD with shorter
recovery of consciousness, with many other citations
suggesting no beneficial effects on the coma recovery.6,10,13,18
Other authors have suggested IV quinine dosage
regimen may be associated with multiple adverse effects,
which lead to poor compliance and side effects including,
cinchonism, cardiac arrythmias, hypotension, vomiting and
abdominal pain, thrombocytopenia, anaemia, partial hearing
loss/tinnitus and hypoglycaemia.2,4,6,17,18,21-23 Many authors
have cited that qLD was affiliated more with the development
of these side-effects rather than the no qLD
regimen.9,13,14,16,18,20,24,25We observed no difference in terms
of adverse effects except thrombocytopenia which was higher
in Group A as compared to Group B. 
A few limitations of this study include its
retrospective design and patient sample from a single
hospital. Also, while studying malaria cases for a period of
eight years, we encountered deficient data in the compiled
records, leading to elimination of such cases. Attention in
these areas is advised for future research to collate significant
results. Paucity of data from South Asian countries should be
addressed with well designed prospective clinical trials which
we are planning to conduct with the baseline information
from the current study. 
Conclusion 
This study showed that quinine loading dose may be
more effective than uniform dose in rapid fever clearance but
it is also associated with higher toxicity. Maintenance dose of
quinine maybe prescribed in severe falciparum malaria
because of its better safety profile. Further well-designed,
prospective studies are needed to directly demonstrate the
impact of loading dose on parasitemia reduction and
consciousness recovery in severe falciparum malaria. 
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